Laurie Stelzer - Jan 20, 2023 Form 4 Insider Report for Mirati Therapeutics, Inc. (MRTX)

Role
CFO
Signature
/s/ Reena R. Desai, Attorney-in-Fact
Stock symbol
MRTX
Transactions as of
Jan 20, 2023
Transactions value $
$0
Form type
4
Date filed
1/24/2023, 03:00 PM
Previous filing
Jun 10, 2022
Next filing
Jun 2, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRTX Common Stock Award $0 +26.9K +46.48% $0.00 84.7K Jan 20, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MRTX Employee Stock Option (Right to Buy) Award $0 +45.5K $0.00 45.5K Jan 20, 2023 Common Stock 45.5K $45.66 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This represents a Restricted Stock Unit grant with a vesting period of 4 years that vests 25% annually from grant date.
F2 25% of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, and 1/48th of the shares subject to the Option shall vest each month thereafter until fully vested.